CommercialPrior AuthMedium impact
Ilumya (J3256) update
Blue Cross Blue Shield of Rhode Island·RI · Dermatology, Rheumatology·Physician / Facility
Effective date
Aug 1, 2024
We identified it
Jun 19, 2026
Summary
Ilumya (J3256) drug injections now require prior authorization for Commercial members, correcting an error where it was previously listed as not needing PA. Providers must contact Prime Therapeutics for future prior authorization requests and can contact Provider services to adjust currently denied claims.
Action Required
Immediately: Update billing workflows to require prior authorization from Prime Therapeutics before administering Ilumya (J3256) injections for Commercial members. Contact Provider services to have any currently denied claims adjusted. Update encounter forms and EMR templates to remind providers of PA requirement before treatment.